| Q47237585 | A systematic review and meta-analysis evaluating ischemic conditioning during percutaneous coronary intervention |
| Q38125624 | Adiponectin: mechanisms and new therapeutic approaches for restoring diabetic heart sensitivity to ischemic post-conditioning |
| Q90642839 | Adropin reduces hypoxia/reoxygenation-induced myocardial injury via the reperfusion injury salvage kinase pathway |
| Q54920287 | An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning. |
| Q35879483 | Cardiac and hepatic role of r-AtHSP70: basal effects and protection against ischemic and sepsis conditions |
| Q64115717 | Cardiac inflammatory CD11b/c cells exert a protective role in hypertrophied cardiomyocyte by promoting TNFR- and Orai3- dependent signaling |
| Q37160528 | Cardiac vulnerability to ischemia/reperfusion injury drastically increases in late pregnancy |
| Q90102755 | Cardiomyocyte damage control in heart failure and the role of the sarcolemma |
| Q42318959 | Cardiomyocyte mitochondria as targets of humoral factors released by remote ischemic preconditioning |
| Q49046559 | Cardioprotection by ischemic postconditioning is abolished in depressed rats: role of Akt and signal transducer and activator of transcription-3 |
| Q39284051 | Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes |
| Q38055280 | Cardioprotection: chances and challenges of its translation to the clinic |
| Q38855645 | Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury. |
| Q36320864 | Chronic intermittent hypoxia exposure improves left ventricular contractility in transgenic mice with heart failure |
| Q37427908 | Controlled Reperfusion Strategies Improve Cardiac Hemodynamic Recovery after Warm Global Ischemia in an Isolated, Working Rat Heart Model of Donation after Circulatory Death (DCD). |
| Q34583556 | Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation – the rat isolated working heart |
| Q28396645 | Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3 |
| Q34181839 | Deciphering STAT3 Signaling in the Heart: Plasticity and Vascular Inflammation |
| Q47968505 | Diazoxide postconditioning induces mitochondrial protein S-nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. |
| Q36895459 | Differential STAT3 signaling in the heart: Impact of concurrent signals and oxidative stress |
| Q54394090 | Effects of ischaemic post-conditioning on the early and late testicular damage after experimental testis ischaemia-reperfusion. |
| Q37871976 | Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum |
| Q35902467 | Endogenous cardioprotection by ischaemic postconditioning and remote conditioning |
| Q48118483 | Enhanced Cardiac S100A1 Expression Improves Recovery from Global Ischemia-Reperfusion Injury |
| Q44796686 | Essential role of EGFR in cardioprotection and signaling responses to A1 adenosine receptors and ischemic preconditioning |
| Q42861824 | Ethanolamine is a novel STAT-3 dependent cardioprotective agent |
| Q38803858 | Evidence of necroptosis in hearts subjected to various forms of ischemic insults. |
| Q54463866 | Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. |
| Q39323549 | Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning |
| Q38255143 | Hexokinases and cardioprotection |
| Q36895483 | High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway |
| Q46359823 | High-Density Lipoprotein Regulation of Mitochondrial Function |
| Q38827052 | High-density lipoprotein, mitochondrial dysfunction and cell survival mechanisms |
| Q42052171 | Hydrogen sulfide post-conditioning preserves interfibrillar mitochondria of rat heart during ischemia reperfusion injury |
| Q36355264 | Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes |
| Q34300508 | Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion |
| Q54168695 | Interleukin-27, a novel cytokine induced by ischemia-reperfusion injury in rat hearts, mediates cardioprotective effects via the gp130/STAT3 pathway. |
| Q46273075 | Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection |
| Q46031696 | Intralipid protects the heart in late pregnancy against ischemia/reperfusion injury via Caveolin2/STAT3/GSK-3β pathway. |
| Q36196031 | Involvement of Glycogen Synthase Kinase-3β and Oxidation Status in the Loss of Cardioprotection by Postconditioning in Chronic Diabetic Male Rats. |
| Q34166155 | Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection |
| Q33605260 | Is there a role for ischaemic conditioning in cardiac surgery? |
| Q28072918 | Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery |
| Q38192849 | Ischaemic conditioning strategies for the nephrologist: a promise lost in translation? |
| Q34457775 | Ischemic conditioning: the challenge of protecting the diabetic heart |
| Q90581463 | Ischemic postconditioning reduces infarct size and microvascular obstruction zone in acute ST-elevation myocardial infarction - a randomized study |
| Q41394648 | JAK-STAT: Getting to the heart of the matter |
| Q37234246 | Kinetics and Signal Activation Properties of Circulating Factor(s) From Healthy Volunteers Undergoing Remote Ischemic Pre-Conditioning |
| Q34636288 | Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction |
| Q38382564 | Long-term outcome following remote ischemic postconditioning during percutaneous coronary interventions-the RIP-PCI trial long-term follow-up |
| Q35750878 | Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease |
| Q35037331 | MG53 participates in ischaemic postconditioning through the RISK signalling pathway |
| Q37225580 | MG53 permeates through blood-brain barrier to protect ischemic brain injury |
| Q89551733 | Mechanical Postconditioning Promotes Glucose Metabolism and AMPK Activity in Parallel with Improved Post-Ischemic Recovery in an Isolated Rat Heart Model of Donation after Circulatory Death |
| Q38391278 | Mitochondria as key targets of cardioprotection in cardiac ischemic disease: role of thyroid hormone triiodothyronine |
| Q38120093 | Molecular mechanisms of ischemic conditioning: translation into patient outcomes |
| Q36908289 | Myocardial AKT: the omnipresent nexus |
| Q34659969 | Myocardial post-conditioning with Danshen-Gegen decoction protects against isoproterenol-induced myocardial injury via a PKCε/mKATP-mediated pathway in rats |
| Q36405244 | N-Acetylcysteine Restores Sevoflurane Postconditioning Cardioprotection against Myocardial Ischemia-Reperfusion Injury in Diabetic Rats. |
| Q98224540 | Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1 |
| Q38046547 | Oxidative stress and myocardial injury in the diabetic heart |
| Q39238269 | Parathyroid Hormone-Related Peptide: A Novel Endocrine Cardioprotective "Conditioning Mimetic". |
| Q34206337 | Perconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions |
| Q35556989 | Pharmacological postconditioning with lactic acid and hydrogen rich saline alleviates myocardial reperfusion injury in rats |
| Q52578576 | Phoenixin: uncovering its receptor, signaling and functions. |
| Q37499879 | Phosphomimetic modulation of eNOS improves myocardial reperfusion and mimics cardiac postconditioning in mice. |
| Q84040560 | Post-ischemic early acidosis in cardiac postconditioning modifies the activity of antioxidant enzymes, reduces nitration, and favors protein S-nitrosylation |
| Q37744271 | Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology |
| Q85122796 | Postconditioning in acute myocardial infarction: Primary angioplasty revisited? |
| Q35426709 | Postconditioning inhibits myocardial apoptosis during prolonged reperfusion via a JAK2-STAT3-Bcl-2 pathway |
| Q27021021 | Postconditioning signalling in the heart: mechanisms and translatability |
| Q42039904 | Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization |
| Q34215871 | RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection |
| Q38125147 | Regulation of cellular gas exchange, oxygen sensing, and metabolic control |
| Q41686281 | Remote Ischemic Conditioning by Effluent Collected from a Novel Isolated Hindlimb Model Reduces Infarct Size in an Isolated Heart Model |
| Q96348665 | Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial |
| Q26830560 | Role of the MPTP in conditioning the heart - translatability and mechanism |
| Q40434074 | Role of toll-like receptor 4 in melatonin-induced cardioprotection |
| Q38256778 | Roles of obese-insulin resistance and anti-diabetic drugs on the heart with ischemia-reperfusion injury |
| Q36895468 | STAT transcription in the ischemic heart |
| Q54390219 | STAT3α interacts with nuclear GSK3beta and cytoplasmic RISK pathway and stabilizes rhythm in the anoxic-reoxygenated embryonic heart. |
| Q41823037 | Short-interval postconditioning protects the bowel against ischaemia-reperfusion injury in rats |
| Q38247701 | Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future |
| Q48961004 | Silencing cardiomyocyte TLR4 reduces injury following hypoxia |
| Q34584267 | Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction |
| Q27001065 | Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress |
| Q38202410 | Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. |
| Q55088026 | Study of respiratory chain dysfunction in heart disease. |
| Q34458657 | Sustained Ligand-Activated Preconditioning via δ-Opioid Receptors |
| Q50130549 | TNF receptor-activated factor 2 mediates cardiac protection through noncanonical NF-κB signaling |
| Q41239818 | TNFR2 Stimulation Promotes Mitochondrial Fusion via Stat3- and NF-kB-Dependent Activation of OPA1 Expression |
| Q37767172 | TNFα in myocardial ischemia/reperfusion, remodeling and heart failure |
| Q36148170 | TNFα protects cardiac mitochondria independently of its cell surface receptors |
| Q39046345 | Tackling myocardial ischemic injury: the signal transducer and activator of transcription 3 (STAT3) at a good site |
| Q38010782 | Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy |
| Q51124858 | The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. |
| Q47100578 | The RISK pathway and beyond. |
| Q99615238 | The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction |
| Q48238697 | The SAFE pathway for cardioprotection: is this a promising target? |
| Q47255415 | The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs |
| Q36072077 | The immunosuppressant FTY720 prolongs survival in a mouse model of diet-induced coronary atherosclerosis and myocardial infarction. |
| Q38191219 | The impact of ischemia-reperfusion injury on the effectiveness of primary angioplasty in ST-segment elevation myocardial infarction |
| Q38274962 | The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. |
| Q38318626 | Trans-system mechanisms against ischemic myocardial injury |
| Q38075417 | Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. |
| Q55296393 | Transplantation of Hearts Donated after Circulatory Death. |
| Q38542449 | Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning |
| Q38790211 | Understanding STAT3 signaling in cardiac ischemia. |
| Q37838085 | When are pro-inflammatory cytokines SAFE in heart failure? |